Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

Thousands of Massachusetts biotech employees face job losses amid industry turmoil. Laid-off workers share their struggles ...

We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

Vertex Pharmaceuticals ( VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically ...

Now, it’s worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for ...

Even with the S&P 500 near an all-time high, there are plenty of compelling growth, dividend, and value stocks to buy now.

Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider ...

Strand Therapeutics announced on Thursday that it landed a $153 million Series B funding led by Kinnevik. The company’s ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $460.0 for Vertex Pharmaceuticals, spanning the last ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Fintel reports that on August 6, 2025, Wells Fargo upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...